Almirall closes gap in product portfolio through commercialization agreement with MC2

Spanish dermatology company Almirall's purchase of European rights for MC2 Therapeutics-developed drug gives the company a much-needed treatment for patients suffering from mild or moderate psoriasis.
Photo: Almirall / PR
Photo: Almirall / PR
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN

Last week's license, collaboration and commercialization agreement between Spanish dermatology company Almirall and Danish pharmaceutical firm MC2 Therapeutics on European rights to the drug Wynzora closes a pipeline gap in Almirall's portfolio of treatments for patients with psoriasis.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading